Table 3.
Strain specific effectiveness of two doses of rotavirus vaccine* against hospital admission with rotavirus, Bolivia
| Group | No/total (%) | Vaccine effectiveness (95% CI) | |
|---|---|---|---|
| Crude | Adjusted | ||
| G9P[8] hospital admission | |||
| Cases | 52/77 (68) | ||
| Non-diarrhea controls† | 233/253 (92) | 86 (71 to 93) | 85 (69 to 93) |
| Test negative controls‡ | 510/586 (87) | 80 (64 to 89) | 80 (60 to 90) |
| G3P[8] hospital admission | |||
| Cases | 30/42 (71) | ||
| Non-diarrhea controls† | 126/130 (97) | 92 (70 to 98) | 93 (70 to 98) |
| Test negative controls‡ | 510/586 (87) | 72 (23 to 89) | 74 (22 to 91) |
| G2P[4] hospital admission | |||
| Cases | 45/56 (80) | ||
| Non-diarrhea controls† | 163/180 (91) | 68 (16 to 88) | 69 (14 to 89) |
| Test negative controls‡ | 510/586 (87) | 60 (14 to 81) | 59 (7 to 78) |
| G9P[6] hospital admission | |||
| Cases | 7/14 (50) | ||
| Non-diarrhea controls† | 31/43 (72) | 88 (25 to 98) | 87 (19 to 98) |
| Test negative controls‡ | 510/586 (87) | 77 (33 to 93) | 80 (37 to 94) |
*Cases and controls were considered vaccinated with two doses if the most recent dose was administered ≥14 days before date of case’s hospital visit.
†For non-diarrheal controls, crude vaccine effectiveness includes only vaccination in model; adjusted vaccine effectiveness for model with G9P[8] includes sex; model for G3P[8] includes number of children rooms in home; model for G2P[4] includes number of children in home and maternal education; model for G9P[6] includes only vaccination.
‡For test negative controls, crude vaccine effectiveness adjusts only for hospital, age in months, and month/year of birth; adjusted vaccine effectiveness for G9P[8] includes hospital, age in months, month/year of birth, and sex; G3P[8] includes hospital, age in months, month/year of birth, sex, and maternal education; G2P[4] includes hospital, age in months, month/year of birth, and number of children in home; G9P[6] includes hospital, age in months, and month/year of birth.